Pharmacy Times

DECEMBER 5, 2022

Teplizumab is a humanized IgG1? Fc-nonbinding anti-CD3 monoclonal antibody that blocks T cells, preventing them from attacking beta cells.

123

123

pharmaphorum

JUNE 8, 2021

US healthcare group Carbon Health has made a move into digital care for patients with chronic conditions, buying diabetes-focused startup Steady Health. He will work on the strategy of delivering healthcare through multiple channels – in-person clinics, home-based care and consumer health tools.

Communication 58

Communication 58

Drug Topics

FEBRUARY 6, 2024

A new study found that over a quarter of participants with type 1 daiebets exhibited clinically relevant levels of posttraumatic stress symptoms related to a diabetes event that they experienced.

201

201

Pharmacy Times

JULY 20, 2023

Despite the surge in new diabetes cases, the treatment options in in children remain limited.

94

94

Pharmacy Times

OCTOBER 25, 2022

SGLT-2 inhibitors, GLP-1 receptor agonists, and a non-steroidal mineralocorticoid receptor are all showing promise in the prevention and management of diabetic kidney disease.

123

123

Drug Topics

MARCH 20, 2023

Various issues were mitigated when patients were given proper training and supplies.

98

98

PharmExec

NOVEMBER 9, 2023

Healthy Food Rx provides home-delivered medical prescriptions of healthy food to help address diabetes.

97

97

Pharmacy Is Right For Me

JANUARY 3, 2024

Linda Gutierrez-Miller, one such student, embarked on a journey to answer these questions, ultimately choosing a career path that aligns with her goals of making a substantial impact and aiding a diverse range of individuals—clinical pharmacy. Additionally, she holds the title of Certified Diabetes Care and Education Specialist (CDCES).

Insurance 306

Insurance Communication Patient Care 306

Drug Store News

FEBRUARY 1, 2023

Clinical Trial Services will recruit patients at 39 proact 1 (REGEN-006) clinical sites, using a machine learning model to identify patient populations that align with trial inclusion/exclusion criteria.

98

98

Pharmacy Times

JANUARY 3, 2024

Liraglutide, a glucagon-like peptide 1 receptor agonist, has shown a clinically and significant reduction in glycated hemoglobin for those with type 2 diabetes.

149

149

Pharmacy Times

AUGUST 10, 2022

Meta-analysis of randomized controlled trials adds to growing evidence around certain antihypertensive drug classes showing promise for primary or secondary prevention of diabetes.

123

123

STAT

MARCH 21, 2024

The last decade has seen billions of dollars flow into digital health companies that promise to improve outcomes for the 38 million Americans living with type 2 diabetes. As a result, they don’t reduce health care spending — they drive it up.

135

135

pharmaphorum

MARCH 22, 2024

First report from PHTI concludes that digital health technologies for diabetes management deliver minimal clinical benefit and raise healthcare costs

115

115

Pharmacy Times

JUNE 30, 2023

Plant-based insulin contains all 3 peptides that are found in insulin naturally produced by the body.

123

123

Pharmacy Times

JULY 15, 2022

The FDA approved tirzepatide for the treatment of type 2 diabetes on May 13, 2022.

FDA 123

FDA 123

Fierce Pharma

FEBRUARY 6, 2024

In a midstage trial, Eli Lilly’s star diabetes and weight-loss drug tirzepatide showed promise in fatty liver disease, a difficult-to-treat condition that doesn’t yet have an FDA-approved therapy.<

FDA 118

FDA 118

Pharmafile

JANUARY 26, 2023

Published date: 26/01/2023 Summary: 26 January 2023 Galway, Ireland - Orbsen Therapeutics Limited (“Orbsen”), a global leader in stromal cell immunotherapies, today announces encouraging headline interim results from the EU Horizon 2020-funded NEPHSTROM clinical trial for Diabetic Kidney Disease (NEPHSTROM). read more

40

40

Drug Store News

NOVEMBER 3, 2022

Walgreens invests in training to equip pharmacists with expert knowledge to address the specific challenges of this chronic, complex condition.

98

98

Drug Store News

NOVEMBER 3, 2022

Walgreens invests in training to equip pharmacists with expert knowledge to address the specific challenges of this chronic, complex condition.

98

98

Fierce Healthcare

FEBRUARY 29, 2024

Telemedicine clinic Virta Health believes its members can achieve significant and sustained improvement in weight loss, even if a patient has stopped taking a GLP-1 drug, a newly released paper in | A new study in Diabetes Therapy from Virta Health says the company's carbohydrate restricted nutrition therapy allows patients who no longer want (..)

138

138

Drug Topics

DECEMBER 1, 2023

A Q&A with Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP, director of education and training in diabetes technology at the Cleveland Clinic.

112

112

The Checkup by Singlecare

NOVEMBER 14, 2023

You’ve likely heard of Type 1 and Type 2 diabetes, but you may not have heard of this third type. Type 3 diabetes is a term used by some researchers to refer to emerging data that shows a link between insulin resistance and dysfunction of a hormone called insulin-like growth factor (IGF-1), which may be a causal factor in Alzheimer’s disease.

Mayo Clinic 111

Mayo Clinic Immunization 111

The Checkup by Singlecare

APRIL 12, 2024

The short supply of this Type 2 diabetes drug has been the subject of many headlines and social media posts. clinical pharmacy program director at Harbor Health. a clinical pharmacist practitioner in Minnesota. a clinical pharmacist practitioner in Minnesota. Looking for an Ozempic shortage update?

Pharmacy Program Director 105

Pharmacy Program Director Labelling FDA Hospitals 105

PharmaShots

MARCH 21, 2023

Shots: The first patient has been dosed in a P-IIa clinical trial evaluating the safety, tolerability, and efficacy of two doses of TLC-3595 (selective inhibitor of acetyl-CoA carboxylase 2) in 50 overweight or obese patients with insulin resistance incl. of therapy while additional exploratory EPs incl.

Compounding 40

Compounding FDA 40

Pharmacy Times

OCTOBER 1, 2022

Empagliflozin has been found to lower the risk of death due to cardiovascular events and the number of first and recurrent heart failure hospitalizations.

Hospitals 122

Hospitals 122

STAT

NOVEMBER 15, 2023

LONDON — Clinical trials have shown that lifestyle programs — which include diet, exercise, and behavioral coaching — can help people in danger of developing type 2 diabetes from tipping into a diagnosis of the condition. A study published Wednesday backs up the idea that they can. Read the rest…

120

120

European Pharmaceutical Review

DECEMBER 7, 2023

Results from a world-first human trial, published in the New England Journal of Medicine , has shown that a drug called baricitinib has promise as the first disease-modifying treatment of its kind for type 1 diabetes, that can be administered as a tablet. 

Immunization 107

Immunization 107

Pharmacy Times

MAY 12, 2023

BI 456906 activates the GLP-1 and glucagon receptors that help to control metabolic function, and could potentially offer clinically relevant benefits for those living with obesity or overweight without type 2 diabetes.

149

149

Drug Topics

AUGUST 29, 2022

Using electronic medical record data from 2018-2020 obtained from 24 medical centers across the US, including Johns Hopkins, University of Colorado, and Mayo Clinic institutions, a new study suggests rates of youth onset type 2 diabetes increased 77% during the first year of the pandemic.

Mayo Clinic 186

Mayo Clinic Medical Records 186

Pharmacy Times

SEPTEMBER 6, 2023

An upcoming large-scale clinical trial of the Glucose Everyday Matters program will evaluate its safety and efficacy in managing type 2 diabetes.

123

123

Fierce Healthcare

JANUARY 30, 2024

A new value-based care enabler focused on endocrinology has launched with a mission to shape the future of diabetes care. Valendo Health uses a phased approach to offer expertise, technology and data-rich tools to help independent physicians enhance clinical capacity, streamline operations and transition to value-based care.

104

104

European Pharmaceutical Review

MARCH 8, 2024

Study design The randomised, double-blind, parallel-group clinical trial compared injectable semaglutide 1.0mg with placebo as an adjunct to standard of care for prevention of progression of kidney impairment and risk of kidney and cardiovascular.

Labelling 96

Labelling 96

European Pharmaceutical Review

OCTOBER 18, 2023

TZIELD (teplizumab-mzwv) has demonstrated TZIELD’s potential to slow disease progression in newly diagnosed children and adolescents with Stage 3 type 1 diabetes. Data from the Phase III PROTECT clinical trial , presented at the 2023 Annual ISPAD Conference, showed that superior beta cell preservation was observed compared to placebo.

110

110

The Checkup by Singlecare

FEBRUARY 7, 2024

If you’ve been diagnosed with diabetes mellitus , dizziness may be an uncomfortably familiar experience. That’s because diabetes can cause blood sugar swings and dehydration—common causes of dizziness or lightheadedness. If you have diabetes and are feeling dizzy, it’s important to tell your healthcare provider.

103

103

The Checkup by Singlecare

FEBRUARY 1, 2024

When someone is diagnosed with diabetes , they must keep a close eye on their blood sugar levels—but, surprisingly, they must also keep a close eye on their feet. People with diabetes are more prone to swelling in the lower legs and feet, a condition called lower extremity edema. Elevate your feet.

Dosage 105

Dosage 105

European Pharmaceutical Review

DECEMBER 5, 2023

billion, enabling the Swiss pharma company to add a range of incretin treatments for obesity and diabetes to its portfolio. Carmot Therapeutics’ lead asset CT-388 is a Phase-II ready dual GLP-1/GIP agonist with best-in-class potential as a treatment for obesity in individuals with and without type 2 diabetes.

98

98

Pharmafile

MARCH 22, 2024

Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorisation for Awiqli (once-daily basal insulin icodec) for the treatment of diabetes in adult patients.

59

59